ProQR Therapeutics N.V. Company Profile (NASDAQ:PRQR)

ProQR Therapeutics N.V. trades on the NASDAQ under the ticker symbol "PRQR."

ProQR Therapeutics N.V. (NASDAQ:PRQR) released its earnings results on Wednesday, May, 17th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.02. View ProQR Therapeutics N.V.'s Earnings History.

ProQR Therapeutics N.V. is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for ProQR Therapeutics N.V..

4 equities research analysts have issued 12-month target prices for ProQR Therapeutics N.V.'s stock. Their forecasts range from $4.50 to $40.00. On average, they expect ProQR Therapeutics N.V.'s stock price to reach $16.38 in the next year. View Analyst Ratings for ProQR Therapeutics N.V..

Here are some recent quotes from research analysts about ProQR Therapeutics N.V. stock:

• 1. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (9/13/2017)
• 2. HC Wainwright analysts commented, "Emile Yu – (212-916-3972) / [email protected]/* */ Takeaways From the R&D Day We see multipronged value going forward after last week’s R&D Day. We believe that in the last three years since its IPO, ProQr has executed successfully on a transformation from a one-oligo CF company to an RNA- platform pipeline with multiple orphan/pediatric indications on deck. In doing so, the company has elected to make RNA technology its core competency, and is now doubling down by leveraging this core competency to hit multiple orphan targets. Meanwhile, as we look at the development and clinical plan, we applaud the array of indications that appears designed to minimize risk in formulation and delivery, and shorten development/regulatory time. According to management, the current goal is to have three clinical programs with data by end-2018. In our view, this looks achievable, with Phase 1b CF data on tap for this Sept, the IND for the Phase 1 LCA study now open, and a study in EB planned for 2018. Of note, we highlight that the rising programs in ophtho and derm may allow for a short trial and regulatory timetable, potentially even beating the CF program on a race to commercial value, all else equal." (6/20/2017)

Some companies that are related to ProQR Therapeutics N.V. include Madrigal Pharmaceuticals (MDGL), Stemline Therapeutics (STML), Oxford BioMedica plc (OXB), Immune Design Corp. (IMDZ), Arrowhead Pharmaceuticals (ARWR), Forward Pharma A/S (FWP), Ardelyx (ARDX), DURECT Corporation (DRRX), uniQure N.V. (QURE), Circassia Pharmaceuticals PLC (CIR), Chimerix (CMRX), Tocagen (TOCA), Mast Therapeutics (SVRA), Pieris Pharmaceuticals (PIRS), ObsEva SA (OBSV), Faron Pharmaceuticals Oy (FARN), Ovid Therapeutc (OVID) and OncoCyte Corp (OCX).

ProQR Therapeutics N.V.'s management team includes the folowing people:

• Daniel De Boer, Founding Chief Executive Officer
• Gerard Platenburg, Co-Founder, Chief Innovation Officer
• Smital Shah, Chief Financial Officer
• Rene K. Beukema, Chief Corporate Development Officer and General Counsel
• Noreen Henig, Chief Development Officer

ProQR Therapeutics N.V.'s stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (10.36%), Redmile Group LLC (6.69%), INVUS PUBLIC EQUITIES, L.P. (6.00%), Artal Group S.A. (2.10%), Janus Henderson Group PLC (1.63%) and Sphera Funds Management LTD. (1.38%). View Institutional Ownership Trends for ProQR Therapeutics N.V..

ProQR Therapeutics N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC. View Insider Buying and Selling for ProQR Therapeutics N.V..

ProQR Therapeutics N.V.'s stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Artal Group S.A. and Redmile Group LLC. View Insider Buying and Selling for ProQR Therapeutics N.V..

Shares of ProQR Therapeutics N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ProQR Therapeutics N.V. stock can currently be purchased for approximately $6.20.